Is FDA Becoming Too Lax With its Drug Approval Standards? Senior FDA Officials Discuss

From industry to academia, commenters have argued that the US Food and Drug Administration’s (FDA) drug approval standards are becoming inappropriately low and that the required postapproval evaluations are either inadequate or left undone.

But three senior FDA officials offered several counterpoints on Monday at the fifth annual Biopharma Congress in Washington, DC.